You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Bendamustine for the first-line treatment of chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • Reference number: TA216
  • Published:  23 February 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Leukaemia (lymphocytic) - bendamustine: Evidence Review Group report - factual accuracy check

Leukaemia (lymphocytic) - bendamustine: Evidence Review Group report - factual accuracy check
Leukaemia (lymphocytic) - bendamustine: Evidence Review Group report - factual accuracy check
23 December 2010
(52.58 Kb 15 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 17 December 2010

Back to top